2 型糖尿病市场，按药物类别、按给药途径、按最终用户、按配销通路、按地理位置

预计 2024 年 2 型糖尿病市值为 398.7 亿美元，预计到 2031 年将达到 671.4 亿美元，2024 年至 2031 年年复合成长率(CAGR) 为 7.7%。

图 1. 2 型糖尿病市场占有率 (%)（按地区），2024 年

2型糖尿病是一种慢性代谢性疾病，其特征是由于胰岛素抗性或胰岛素相对缺乏而导致高血糖。它是最常见的糖尿病形式，占全球所有糖尿病诊断病例的 90% 以上。该疾病是全球主要的公共卫生问题，因为已开发国家和发展中国家的肥胖水平增加以及人口老化导致其盛行率不断上升。 2型糖尿病管理和治疗的市场规模庞大且稳定成长。目前的治疗方案旨在透过增加身体对胰岛素的敏感性、减少肝臟中葡萄糖的产生、延迟肠道对葡萄糖的吸收或增加剩余功能性β细胞的胰岛素分泌来降低血糖水平。

市场动态：

全球第2型糖尿病市场的主要驱动因素是肥胖和体力活动水平低下，尤其是在城市人口中，导致第2型糖尿病发病率上升。根据美国疾病管制与预防中心在 2023 年 4 月发表的一篇文章，美国约有 3,800 万人患有糖尿病，约占每 10 人中就有 1 人患有糖尿病。这些病例中约 90-95% 被归类为第 2 型糖尿病。虽然第 2 型糖尿病传统上多见于 45 岁及以上的人群，但其在儿童、青少年和年轻人中的发病率呈上升趋势。加强研究力度开发更有效、副作用更少的药物也带来了巨大的成长机会。然而，与糖尿病护理和管理相关的高昂费用阻碍了低收入和中等收入国家更广泛地获得治疗。严格的法规和漫长的药品审批期限也带来了挑战。

研究的主要特点：

• 该报告对全球第2型糖尿病市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它阐明了不同细分市场的潜在收入成长机会，并解释了该市场有吸引力的投资主张矩阵。
• 这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
• 它根据以下参数描述了全球 2 型糖尿病市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
• 该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球 2 型糖尿病市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
• 利害关係人可以透过用于分析全球 2 型糖尿病市场的各种策略矩阵轻鬆做出决策。

目录

第一章：研究目标与假设

• 研究目标
• 假设
• 缩写

第 2 章：市场范围

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map (COM)

第 3 章：市场动态、法规与趋势分析

• 市场动态
  • 司机
  • 限制
  • 市场机会
• 影响分析
• 市场走向
• 最近的发展
• 收购和合作场景
• 技术概览
• 监管场景
• 定价分析
• PEST分析

第 4 章：全球 2 型糖尿病市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第 5 章：2019 - 2031 年全球 2 型糖尿病市场（按药物类别）（十亿美元）

• 概述
• 二肽基肽酶 4 抑制剂
• 胰高血糖素样胜肽 1 受体激动剂
• 双胍类
• 钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂
• 其他的

第 6 章：2019 年至 2031 年全球 2 型糖尿病市场（按给药途径）（十亿美元）

• 概述
• 口服
• 注射用

第 7 章：全球 2 型糖尿病市场，按最终用户划分，2019 - 2031 年（十亿美元）

• 概述
• 家庭护理设置
• 医院和诊所
• 学术及研究机构
• 其他的

第 8 章：全球 2 型糖尿病市场，按配销通路，2019 年 - 2031 年，（十亿美元）

• 概述
• 医院药房
• 零售药局
• 网路药局

第 9 章：2019 - 2031 年全球 2 型糖尿病市场（按地区）（十亿美元）

• 介绍
• 北美洲
• 我们
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 拉丁美洲其他地区
• 欧洲
• 英国
• 德国
• 义大利
• 法国
• 西班牙
• 俄罗斯
• 欧洲其他地区
• 亚太地区
• 中国
• 印度
• 日本
• 东协
• 澳洲
• 韩国
• 亚太地区其他地区
• 中东
• 海湾合作委员会
• 以色列
• 中东其他地区
• 非洲
• 北非
• 中非
• 南非

第 10 章：竞争格局

• 公司简介
  • Novo Nordisk
  • Sanofi
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Boehringer Ingelheim
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Daiichi Sankyo Company, Limited
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Torrent Pharmaceuticals Limited

第 11 章：分析师观点

• 命运之轮
• 分析师观点
• 连贯的机会图

第 12 章：参考文献与研究方法

• 参考
• 研究方法论

The type 2 diabetes market is estimated to be valued at USD 39.87 Bn in 2024 and is expected to reach USD 67.14 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031.

Figure 1.Type 2 Diabetes Market Share (%), By Region, 2024

Type 2 diabetes is a chronic metabolic disease characterized by high blood sugar levels due to insulin resistance or relative lack of insulin. It is the most common form of diabetes accounting for over 90% of all diagnosed cases of diabetes worldwide. The disease is a major global public health concern due to its rising prevalence driven by increasing obesity levels as well as aging populations across both developed and developing countries. The market size for type 2 diabetes management and treatment is vast and growing steadily. Current therapeutic options aim to lower blood sugar levels by increasing the body's sensitivity to insulin, reducing glucose production in the liver, delaying glucose absorption from the intestine, or increasing insulin secretion from the remaining functioning beta cells.

Market Dynamics:

The global type 2 diabetes market is primarily driven by the increasing prevalence of obesity and low physical activity levels especially among urban populations leading to the rising incidence of type 2 diabetes. According to an article published by the Centers for Disease Control and Prevention in April 2023, about 38 million individuals in the U.S. are affected by diabetes, representing roughly one out of every 10 people. Approximately 90-95% of these cases are classified as type 2 diabetes. While type 2 diabetes traditionally manifests in individuals aged 45 and older, there is a growing trend of its occurrence among children, teenagers, and young adults. Increased research efforts to develop more effective medications with fewer side effects also present significant growth opportunities. However, high costs associated with diabetes care and management inhibits broader access to treatment in low and middle-income countries. Stringent regulations and long drug approval timelines also pose challenges.

Key Features of the Study:

• This report provides an in-depth analysis of the global type 2 diabetes market, and provides market size (USD BN) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global type 2 diabetes market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novo Nordisk, Sanofi, Eli Lilly and Company, Merck & Co., Inc., Boehringer Ingelheim, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Novartis AG, GlaxoSmithKline plc, Pfizer Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, Roche Holding AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, and Torrent Pharmaceuticals Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global type 2 diabetes market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global type 2 diabetes market

Market Segmentation

• By Drug Class:
  • Dipeptidyl Peptidase-4 Inhibitors
  • Glucagon-like peptide 1 receptor agonists
  • Biguanides
  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors
  • Others
• By Route of Administration:
  • Oral
  • Parenteral
• By End User:
  • Homecare Settings
  • Hospitals & Clinics
  • Academic & Research Institutes
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Novo Nordisk
  • Sanofi
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Boehringer Ingelheim
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Daiichi Sankyo Company, Limited
  • Abbott Laboratories
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Torrent Pharmaceuticals Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By End User
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pricing Analysis
• PEST Analysis

4. Global Type 2 Diabetes Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 impact on the market

5. Global Type 2 Diabetes Market, By Drug Class, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Dipeptidyl Peptidase-4 Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Glucagon-like peptide 1 receptor agonists
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Biguanides
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Sodium-glucose cotransporter 2 (SGLT2) inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Type 2 Diabetes Market, By Route of Administration, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Type 2 Diabetes Market, By End User, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Homecare Settings
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Hospitals & Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Academic & Research Institutes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Type 2 Diabetes Market, By Distribution Channel, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

9. Global Type 2 Diabetes Market, By Region, 2019 - 2031, (USD BN)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Company Profiles
  • Novo Nordisk*
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Strategies
  • Sanofi
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Boehringer Ingelheim
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Daiichi Sankyo Company, Limited
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Torrent Pharmaceuticals Limited

11. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact